Objective: Dendritic cells (DCs) activation is important in atherosclerosis and coronary heart disease, but the mechanisms regulating activation of dendritic cells remain largely unclear. The aim of this study was to evaluate the effect of transcription factor Kruppel-like factor 2 (KLF2) in the proinflammatory activation of DCs in acute coronary syndrome. Methods and Results: In this study, the expression of CD80 and KLF2 was detected in DCs in normal health controls, patients with stable angina (SA), and acute coronary syndrome (ACS). Our study found that compared with normal control and SA, KLF2 expression in DCs is reduced in patients with ACS. Moreover, the surface expression of CD80 was increased in ACS. In vitro experiment, we found that ox-LDL could increase CD80 expression and decrease KLF2 expression. Furthermore, down-regulated KLF2 could in turn increase CD80 expression via NF-κB pathway. Conclusions: These observations identify KLF2 as a novel negative regulator of DC function and it may play an essential role in DC activation in ACS.
Introduction
Atherosclerosis (AS) is a multifactorial process and one of its outcomes, coronary heart disease (CAD), is the leading cause of death worldwide. Atherosclerosis involves endothelial dysfunction, genetic and hemodynamic factors as well as other acquired and modifiable risk Fang et 
Isolation of DCs
Blood was drawn from an antecubital vein into a vacutainer tube (Beckon Dickinson,USA) containing 3.2% sodium citrate prior to drug treatment when the patients were admitted to the hospital. Isolation of human peripheral blood mononuclear cells (PBMCs) was performed using Ficoll-Hypaque density gradient centrifugation following the manufacturer's protocol (Human lymphocyte separation medium from Chinese Academy of Medical Sciences Institute of Biomedical Engineering, China).
Purified CD14+ monocytes isolated from PBMCs by MACS were cultured with recombinant human IL-4 (rhIL-4; 100 U/mL, PeproTech, USA) and recombinant human granulocyte-macrophage colony-stimulating factor (Recombinant Human GM-CSF, 100 U/mL, PeproTech, USA) for 7 days. The floating cells with short dendrite were further isolated using CD11c bead-based MACS, which were named peripheral blood DCs with a purity of more than 95%.
RNA interference and transfection
Small interfering RNAs (siRNAs) were designed and synthesized by RiBoBio Co. Ltd (Guangzhou, China). The sequences of human siRNAs were: KLF2 siRNA: sense 5'-GGA UGA UCU UCG ACG UGG A-3', antisense 5'-UCC ACG UCG AAG AUC AUC C-3; unrelated siRNA: sense 5'-UUC UCC GAA CGU GUC ACG UdTdT-3', antisense 5'-dTdT AAG AGG CUU GCA CAG UGC A-3'. The transfection of siRNA in the cultured human DCs was performed in 6-well plates at 70% confluence, and at a final concentration of 50 nmol/L using X-tremeGENE siRNA transfection reagent (Roche). The mRNA level expression was detected after 24 
Preparation of LDL and copper-oxidized LDL
Ox-LDL was prepared as described previously [14] .
Cell cultures
Dendritic cells from health volunteers were prepared as described previously. After dendritic cells transfected with non-trageting siRNA or KLF2 siRNA, cells were stimulated with PBS (control) or 40 ug/ ml ox-LDL for 8 hours. In some experiments, DCs were pretreated for 30 min with NF-κB specific inhibitor( PDTC, 10 µmol/L) (Sigma, USA) before further experiments.
Flow cytometric analysis
The expression of TLR4 and CD80 on DCs was performed by flow cytometry using phycoerythrin (PE) antihuman TLR4 antibody (BioLegeng, USA) and FITC anti-human CD80 (BioLegeng, USA) according to the manufacturer's instructions. Briefly, 20μl PE-conjugated mouse antihuman TLR4 antibody was incubated with 100 μl whole blood for 30 min at room temperature in the dark. The mixture was washed in stain buffer containing bovine serum albumin and sodium azide. Cells were re-suspended in 500 μl stain buffer and analyzed by flow cytometer (LSRII, Becton Dickinson, USA). A negative control was prepared by incubating with an isotype-matched control antibody (IgG2a).
RT-PCR analysis
The level of KLF2 mRNA expression was analyzed by real-time reverse transcription-polymerase chain reaction (Real-time RT-PCR). Cells were harvested from cells or tissues, and total RNA was isolated using Trizol reagent (Invitrogen, USA) according to the manufacturer's recommendations. RNA concentration and its purity were measured by a spectrophotometer. One microgram of total RNA was reversely transcripted into cDNA using RNA PCR Kit (Takara Biotechnology, Japan) and the cDNA was used as a template. The realtime PCR was carried out with Applied Biosystems Step One Real-Time PCR System (Applied Biosystem, USA) according to the manufacturer's protocol. A housekeeping genes GAPDH was used as an internal control for the PCRs. The sequences of the primers were presented as follows: KLF2 sense-primer: 5'-CTA CAC CAA GAG TTC GCA TCT G-3', antisense-primer: 5'-CCG TGT GCT TTC GGT AGT G-3'; GAPDH senseprimer: 5'-TGT TGC CAT CAA TGA CCC CTT-3', antisense-primer: 5'-CTC CAC GAC GTA CTC AGC G-3'. The PCR reaction mixture was prepared with the SYBR Green I (Takara Biotechnology, Japan), cDNA, and the primers following the manufacturer's protocol. The amount of gene expression was then calculated as the difference (ΔCt) between the Ct value of target gene and the Ct value of GAPDH. Fold changes in target gene mRNA were determined by the formula 2 -ΔΔCt .
Western blot analyses
Equal protein amounts were loaded onto SDS-PAGE gels. After running gels, proteins were transferred onto nitrocellulose membranes. Membranes were blocked in 5% nonfat milk and primary antibody incubations were performed with 3% BSA (overnight at 4°C). Antibodies used were specific Abs against the KLF2 (Rabbit polyclonal to human KLF2, Abcam, USA). Then membranes were incubated with peroxidaseconjugated secondary antibodies at room temperature for 2 hours. Specific band was detected with chemiluminescence assay (ECL detection reagents, Pierce) and recorded on x-ray film. Designed software was used to quantify the intensities of bands.
Electrophoresis Mobility Shift Assay (EMSA)
Nuclear extracts (15ug per lane) from the DCs were prepared, and mobility-shift analyses were performed as previously described [15] . DNA probes were generated to the NF-κB consensus sequences as the co-stimulatory molecules CD80 and CD86, or the major histocompatability complex (MHC) class I and II antigens were involved too [17] . Therefore, the levels of CD80 and TLR4 on surface molecules were used to assess the activation of DCs. Our study found that the surface expression of TLR4 and CD80 for DCs in normal control, SA group and ACS group was 47.75% ± 2.40%, 50.9%± 2.27%, and 81.40 % ± 1.64%, respectively. The frequencies of CD80 and TLR4 positive DCs were significantly higher in patients with ACS than in which in SA patients (P<0.001) or normal controls (P<0.001) (Fig. 1) . No statistically significant difference was detected between normal control and SA group (P>0.05). Based on these data, we concluded that the state of DCs in patients with ACS was more active than in patients with SA and normal controls.
KLF2 was down-regulated in DCs in the patients with ACS
We next intended to determine KLF2 expression in DCs in normal control, patients with SA and patients with ACS. Real-time PCR showed that compared with normal control; there (Fig. 2A) . The protein level of KLF2 in DCs was also determined in our study. Coincident with decreased KLF2 mRNA expression, a distinct reduction of KLF2 protein expression was detected in DCs in ACS. In contrast, the difference of KLF2 protein in normal control and SA was not obvious (Fig. 2B) .
Decreased KLF2 increased the surface expression of CD80 in DCs
Ox-LDL has been reported to be one of the most important stimuli for DCs activation. Figure 3A showed that compared with untreated DCs, ox-LDL stimulation significant reduced KLF2 mRNA expression (control: 1.00±0.00; ox-LDL: 0.71±0.05) (P<0.05). Figure 3B showed that level of KLF2 protein was also down-regulated after stimulation with ox-LDL. Furthermore, the surface expression of CD80 was dramatically elevated in DCs stimulated with ox-LDL (11.20% ± 1.65%), compared with those cultured with PBS (control: 43.13% ± 4.56%) (P<0.001) (Fig. 3C) .
To examine whether there was a causative relationship between the decreased KLF2 and the up-regulated CD80 expession in DCs, we targeted KLF2 in human DCs with siRNA and the expression of CD80 was examined by FACS. Figure 4A showed that compared with non-targeted control siRNA, KLF2 specific siRNA exhibited a strong inhibition on KLF2 mRNA expression (P<0.001) (Fig. 4A) . Furthermore, down-regulated KLF2 could modulate DCs activation, as shown by the expression of CD80 significantly increased from 15.58 % ± 1.10 % on the surface of non-targeted, knockdown DCs to 52.66% ± 7.85 % (P<0.001) (Fig.  4B) .
KLF2 -modulated expression of CD80 involved NF-κB pathway
Nuclear factor κB (NF-κB), as a crucial transcription factor, is involved in the regulation of inflammatory and immune genes, cell proliferation, and apoptosis. To define whether NF-κB was involved in KLF2-modulated DCs activation, DCs were cultured with siRNA in presence or absence of human NF-κB pathway inhibitor (PDTC, 10 µmol/L). Then, electrophoretic mobility shift assay (EMSA) was performed with specific oligonucleotide probes for the NF-κB binding site regions.
As illustrated in Figure 5A Next we sought to explore whether the increased NF-κB activity in KFL2 knockdown DCs was involved in DCs activation. Figure 5C showed that compared with PBS (52.66 % ± 7.82 %), NF-κB specific inhibitor could significantly reduce the surface expression of CD80 in KFL2 knockdown DCs (33.13 % ± 4.57 %) (P<0.001). Therefore, it is plausible to postulate that down-regulated KLF2 modulation leads to CD80 activation via NF-κB signaling pathway.
Discussion
Recent research has shown that inflammation plays a key role in coronary artery disease and other manifestations of atherosclerosis. Immune cells dominate early atherosclerotic lesions, their effector molecules accelerate progression of the lesions, and activation of inflammation can elicit acute coronary syndromes [2] . DCs play a key role in Fig. 5 . NF-κB DNA binding activity in DCs. DCs were cultured as described in Figure legend 4. In some experiments, DCs were pretreated for 30 min with NF-κB specific inhibitor (PDTC, 10 µmol/L) (Sigma, USA) before further experiments. (A) An electronic mobility shift assay was performed with nuclear exacts (30ug/well) from DCs in different cultures to assay NF-κB activity. (B) DNA binding activity of NF-κB was evaluated using the relative method. (C) DCs were sequentially stained with FITC-conjugated anti-CD80 antibody, and the frequency of CD80 positive cells was analyzed statistically by SPSS 13.0. * indicated vs control, ***P<0.001. # indicated vs control siRNA, ###P<0.001. Data are presented as mean±SEM of at least three independent experiments. Fang 
innate and adaptive immunity [18] . During ACS, circulating DCs are markedly decreased. At the same time, DCs accumulate in vulnerable atherosclerotic tissue [19] . Particularly in vulnerable plaques, previous researches have described a high density of tissue-resident DC with frequent T-cell contacts, suggesting their contribution to plaque destabilization [20] . Dyslipidaemia systemically alters DC function and recent findings suggest that DCs play a role in plaque destabilization [21] . Therefore, DCs play an important role in the origination, development and destabilization of atherosclerosis. The systemic as well as local vascular immune systems are involved in the development and progression of atherosclerosis. The development and progression of atherosclerosis is mainly determined by endothelial dysfunction with subsequent adhesion, activation and differentiation of leukocytes as well as by the interaction between antigen-presenting cells and T cells [22] . Recently, research has suggested that a reduction of KLF2 expression at levels that approximate those observed in human subjects with coronary artery disease is biologically relevant [23] . The observation provides evidence in support of the hypothesis that KLF2 is atheroprotective in vivo. Previous studies indicate that KLF2 inhibits monocyte proinflammatory gene expression and phagocytosis. Importantly, KLF2 expression in peripheral blood monocytes of patients with established atherosclerotic disease is reduced by 30% [13] . KLF2 is known to induce eNOS and inhibit VCAM-1 expression in cultured endothelial cells [12] . KLF2 shows reduced expression in response to LPS and in patients with coronary artery disease; its expression is increased by statins. Overexpression represses proinflammatory genes (eg, COX-2, CD40L, MCP-1) [13] . KLF2 is expressed in single-positive CD4 + and CD8 + T cells, induced by statins and rapamycin, and its expression is rapidly extinguished after T-cell activation via the PI3K/AKT signaling pathway [15, [24] [25] [26] .
Previous studies about the immune mechanisms of CAD rarely focus on DCs. Research in the regulating effect of KLF2 in activation of DCs, which play a key role in the atherosclerosis, have been rare. In our study, we found that KLF2 probably plays a key role in repressing activation of DCs in patient with ACS.
In the vivo experiment, we showed that the surface expressions of TLR4 and CD80 in the DCs of patients with ACS are much higher than those in the other two groups. The activation of NF-kB in the DCs of patients with ACS is higher than in those of the other two groups. These findings indicate that the DCs of patients with ACS are more activated and mature, and have a higher level of inflammation, than those in the other two groups. We also demonstrated that the levels of KLF2 expression and transcription in the DCs of patients with ACS are lower than those in the other two groups. The levels of KLF2 expression and transcription are negatively correlated with the level of inflammation, activation and maturity. These indices, however, do not distinguish differentiation between group II and group I. Although patients with SA have atherosclerosis in their coronary artery, their lesions are stable and the atherosclerosis is still at a low level of inflammation. We therefore had reasons to believe that KLF2 inhibits DC activation and carried out in vitro experiments to further demonstrate this.
Fragments of bacteria such as lipopolysaccharides (LPs), modified autoantigens such as oxidized LDL, and heat-shock proteins are recognized by TLR4 and activate the subsequent signaling cascade [27, 28] . Oxidized low density lipoprotein (LDL) is believed to play a key role in the development of atherosclerosis [29] . Therefore, we use oxLDL as the stimulating factor in our in vitro experiment. We found that KLF2 expression and transcription decreased in groups II and IV when stimulated with oxLDL. From the effect of transfection, KLF2 expression and transcription were low or undetected, without obvious diversity. However, the activation of NF-kB of the DCs in group VI was explosively enhanced, which we ascribed to the knockdown of KLF2 gene transcription. Previous studies suggest that NF-kB requires coactivators such as p300CBP or PCAF for transcriptional activation [30, 31] . As such, it is considered that KLF2 may bind to one or more of these coactivators and, as a consequence, render them incapable of assisting NF-kB to induce transcriptional activity. Through the in vivo and in vitro experiments, we have reasoned that Kruppel-like factor 2 (KLF2) signaling inhibits TLR4-induced DC activation in patients with acute coronary syndrome, in which NF-kB participates. 
Cellular Physiology and Biochemistry
Thus far, the precise signaling mechanisms responsible for activation of DCs in the pathogenesis of atherosclerosis remain ill defined. In this study, we describe for the first time that KLF2 signaling downregulates DC activation in patients with CAD. KLF2 signaling may be a new target of antiatherogenic therapy in the future even though there are challenges to improve understanding of certain areas, such as the actual interaction between TLR4 and KLF2. This underscores the novel therapeutic opportunities that will be gained by modulating TLR4, KLF2 and NF-kB to manipulate innate and adaptive immunity for the immune therapy of CAD.
